文献速递炎症性肠病消化道肿瘤与早癌

产肠毒素脆弱拟杆菌通过抑制外泌体miR-149-3p促进肠道炎症与恶性转化

Enterotoxigenic Bacteroidesfragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p.
PubMed 文献 · Gastroenterology · 2021-08-08

本研究探讨产肠毒素脆弱拟杆菌(ETBF)诱发肠道炎症和结直肠癌的机制。采用microRNA测序及体外体内实验发现,ETBF通过METTL14介导的m6A甲基化下调miR-149-3p,进而经PHF5A/KAT2A/SOD2轴促进CRC细胞增殖,且血浆外泌体miR-149-3p在健康对照、IBD和CRC患者中逐渐降低,与ETBF丰度负相关。

要点

  • ETBF通过METTL14介导的m6A甲基化下调miR-149-3p,促进CRC细胞增殖。
  • miR-149-3p靶向PHF5A,经KAT2A mRNA可变剪接反式激活SOD2。
  • 血浆外泌体miR-149-3p从健康对照到IBD和CRC患者逐渐降低,与ETBF丰度负相关。

核心结论

  • ETBF处理细胞来源的外泌体miR-149-3p促进Th17细胞分化,ETBF诱导的结直肠癌变依赖于下调miR-149-3p并促进PHF5A介导的KAT2A RNA可变剪接。
  • 靶向ETBF/miR-149-3p通路是治疗高ETBF载量肠道炎症和CRC患者的潜在策略。

研究设计与样本

  • 采用microRNA测序检测ETBF处理细胞及ETBF接种细胞来源外泌体中的差异表达microRNA。
  • 使用CCK8实验评估ETBF和外泌体对CRC细胞增殖的影响。
  • 在体外和体内实验中确定ETBF介导的miR-149-3p在结肠炎和结肠癌变中的生物学作用及机制。

主要发现

  • ETBF在体外和体内通过下调miR-149-3p促进CRC细胞增殖。
  • ETBF下调miR-149-3p依赖于METTL14介导的N6-甲基腺苷甲基化。
  • miR-149-3p的靶基因PHF5A在ETBF处理CRC细胞后通过调控KAT2A信使RNA可变剪接反式激活SOD2。
  • miR-149-3p可释放于外泌体中,通过调节Th17细胞分化介导细胞间通讯。
  • 血浆外泌体miR-149-3p水平从健康对照到IBD和CRC患者逐渐降低,且与IBD和CRC患者中ETBF丰度负相关。

临床怎么用

  • 血浆外泌体miR-149-3p水平从健康对照到IBD和CRC患者逐渐降低,且与ETBF丰度负相关,提示其可能作为反映ETBF相关肠道炎症和癌变风险的潜在生物标志物。
  • 靶向ETBF/miR-149-3p通路可能是治疗高ETBF载量肠道炎症和CRC患者的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Enterotoxigenic Bacteroides fragilis (ETBF) is strongly associated with the occurrence of inflammatory bowel disease (IBD), colitis-associated colorectal cancer, and colorectal cancer (CRC). However, the mechanism of ETBF-induced intestinal inflammation and tumorigenesis remains unclear. METHODS: microRNA sequencing was used to detect the differentially expressed microRNAs in both ETBF-treated cells and exosomes derived from ETBF-inoculated cells. Cell Counting Kit 8 assays were used to evaluate the effect of ETBF and exosomes on CRC cell proliferation. The biological role and mechanism of ETBF-mediated miR-149-3p in colitis and colon carcinogenesis were determined both in vitro and in vivo. RESULTS: ETBF promoted CRC cell proliferation by down-regulating miR-149-3p both in vitro and in vivo. ETBF-down-regulated miR-149-3p depended on METTL14-mediated N6-methyladenosine methylation. As the target gene of miR-149-3p, PHF5A transactivated SOD2 through regulating KAT2A messenger RNA alternative splicing after ETBF treatment in CRC cells. miR-149-3p could be released in exosomes and mediated intercellular communication by modulating T-helper type 17 cell differentiation. The level of plasma exosomal miR-149-3p was gradually decreased from healthy control individuals to patients with IBD and CRC. miR-149-3p, existing in plasma exosomes, negatively correlated with the abundance of ETBF in patients with IBD and CRC. CONCLUSIONS: Exosomal miR-149-3p derived from ETBF-treated cells facilitated T-helper type 17 cell differentiation. ETBF-induced colorectal carcinogenesis depended on down-regulating miR-149-3p and further promoting PHF5A-mediated RNA alternative splicing of KAT2A in CRC cells. Targeting the ETBF/miR-149-3p pathway presents a promising approach to treat patients with intestinal inflammation and CRC with a high amount of ETBF.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Cao Y, Wang Z, Yan Y, et al. Enterotoxigenic Bacteroidesfragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p. Gastroenterology. 2021. PMID: 34371001. doi:10.1053/j.gastro.2021.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。